Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

BG Medicine Inc reports clinical utility of BGM Galectin-3 test for prediction of near-term rehospitalization in patients with heart failure


Tuesday, 25 Mar 2014 08:31am EDT 

BG Medicine Inc:Announces publication of results, in the American Heart Journal, of an analysis of aggregated data from three large, multicenter clinical research trials in the United States and Europe.Trials demonstrated that elevations of galectin-3 levels in blood, as measured using the BGM Galectin-3 Test, were significantly predictive of rehospitalization for heart failure as early as within the first 30 days following discharge from an initial hospital stay. 

Company Quote

0.4694
 --
29 Oct 2014